Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,535.40
(
0.87%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.75
(
-0.95%
)
Bitcoin
81,017.77
(
0.65%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: ststephensrevenge post# 270569

Thursday, 08/18/2016 8:05:44 PM

Thursday, August 18, 2016 8:05:44 PM

Post# of 347009
Great input to enhance our knowledge and Big Pharma future. I wonder if anyone is paying attention to Reactive Oxygen ...etc and all kinds of Biomarkers can become astronomical. Dr Brekken knows a bit much about Reactive Oxygen and I bet there is a relationship with PS Targeting in that equation

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote